trending Market Intelligence /marketintelligence/en/news-insights/trending/av3hbxmlk_hsjkuernriza2 content esgSubNav
In This List

Oxford BioMedica chief business officer and director plans to retire

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


Oxford BioMedica chief business officer and director plans to retire

Oxford BioMedica PLC said Peter Nolan plans to retire as chief business officer and director of the gene and cell therapy company, effective July 1.

Nolan, who had worked with Oxford BioMedica for over 20 years, will work as a consultant to the company following his retirement.

U.K.-based Oxford BioMedica is involved in the research, development, and bioprocessing of lentiviral vector and cell therapy products for the treatment of various cancers, Parkinson's, central nervous system disorders, and eye conditions.